Multicenter Analysis of mFOLFOX6 with Oxaliplatin Stop-and-Go Strategy Using Oral Uracil-Tegafur with Leucovorin for Unresectable Colorectal Cancer in Elderly Patients  

作　　者：Tetsu Yamamoto Kuniyuki Katano Shinichi Sugimoto Akiyoshi Kanazawa Eiji Hira Hiroshi Takeda Yoshitoshi Sato Yutaka Yamashiro Yoshitsugu Tajima Masahide Ikeguchi 

机构地区：[1]Department of Digestive and General Surgery, Faculty of Medicine, Shimane University, Izumo, Japan [2]Department of Gastroenterological Surgery, Matsue Red Cross Hospital, Matsue, Japan [3]Department of Gastroenterological Surgery, Osaka Red Cross Hospital, Osaka, Japan [4]Department of Gastroenterological Surgery, Tottori Red Cross Hospital, Tottori, Japan [5]Department of Surgery, Saihaku Hospital, Saihaku, Japan [6]Department of Surgery, Shimane Prefectural Central Hospital, Izumo, Japan [7]Division of Surgical Oncology, Faculty of Medicine, Tottori University, Yonago, Japan

出　　处：《Journal of Cancer Therapy》2014年第2期147-154,共8页癌症治疗（英文）

摘　　要：Background: This study evaluated the tolerability and efficacy of intermittent oxaliplatin treatment based on mFOLFOX6 using oral uracil-tegafur(UFT) and leucovorin(LV) maintenance therapy in the treatment of elderly patients with advanced colorectal cancer. Methods: Ten non-elderly patients (70 years) with advanced/recurrent colorectal cancer were enrolled in this prospective, multicenter cooperative group clinical trial. The mFOLFOX6 regimen was administered for eight cycles with maintenance therapy with oral UFT/LV treatment until progression. In cases with disease progression, mFOLFOX6 was reintroduced. Results: Grade 2 peripheral neuropathy was noted in 30.0% and 25.0% of the elderly and non-elderly patients, respectively. The observed time to treatment failure (TTF) was 6.3 months in the elderly patients and 6.4 months in the non-elderly patients. The disease control rate was 83.3% in each group. Conclusion: Our new stop-and-go strategy using oral UFT/LV is well-tolerated and effective even in elderly patients.Background: This study evaluated the tolerability and efficacy of intermittent oxaliplatin treatment based on mFOLFOX6 using oral uracil-tegafur(UFT) and leucovorin(LV) maintenance therapy in the treatment of elderly patients with advanced colorectal cancer. Methods: Ten non-elderly patients (70 years) with advanced/recurrent colorectal cancer were enrolled in this prospective, multicenter cooperative group clinical trial. The mFOLFOX6 regimen was administered for eight cycles with maintenance therapy with oral UFT/LV treatment until progression. In cases with disease progression, mFOLFOX6 was reintroduced. Results: Grade 2 peripheral neuropathy was noted in 30.0% and 25.0% of the elderly and non-elderly patients, respectively. The observed time to treatment failure (TTF) was 6.3 months in the elderly patients and 6.4 months in the non-elderly patients. The disease control rate was 83.3% in each group. Conclusion: Our new stop-and-go strategy using oral UFT/LV is well-tolerated and effective even in elderly patients.

关 键 词：Colorectal Cancer OXALIPLATIN Uracil-Tegafur (UFT) LEUCOVORIN Elderly Patient Stop-and-Go 

分 类 号：R73[医药卫生—肿瘤]